HPV type 16 and 18 L1 capsid protein — Drug Target

All drugs that target HPV type 16 and 18 L1 capsid protein — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Prophylactic vaccine

Phase 3 pipeline (1)

• GSK580299 (Cervarix) · GlaxoSmithKline · Prophylactic vaccine · Oncology / Immunology
  Cervarix is a bivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 16 and 18, preventing infection and cervical cancer development.